Clene Inc. to Share Corporate Update at Emerging Growth Conference

Clene Inc. (NASDAQ: CLNN), a clinical-stage biopharmaceutical company, is set to present a corporate update at the Emerging Growth Conference on August 20, 2025. The presentation, scheduled for 2:20 p.m. ET, will be available via a live webcast through the Events section of Clene’s website and the conference registration link. This event is significant for investors and stakeholders interested in the company's advancements in treating neurodegenerative diseases such as ALS and MS.

The session will include a Q&A segment, offering attendees the opportunity to engage directly with Clene's leadership. Replays of the presentation will be accessible through the conference portal and its YouTube channel, ensuring those unable to attend live can still gain insights into Clene's progress and future directions. The company's focus on improving mitochondrial health and protecting neuronal function positions it as a key player in the biopharmaceutical industry's efforts to address challenging neurodegenerative conditions.

Clene's investigational therapy, CNM-Au8®, represents a novel approach to treating diseases like amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. By targeting mitochondrial function and the NAD pathway, CNM-Au8® aims to enhance central nervous system cells' survival and function while reducing oxidative stress. This presentation at the Emerging Growth Conference underscores the importance of Clene's research and development efforts in the broader context of neurodegenerative disease treatment.

For those interested in learning more about Clene Inc. and its innovative therapies, additional information is available on the company's website. The upcoming conference presentation is a pivotal moment for Clene to showcase its achievements and outline its vision for the future, making it a must-watch event for the investment and biopharmaceutical communities.